Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022
- 11 July 2024
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 38 (9) , 743-751
Abstract
Introduction In recent years, pregabalin has received growing attention due to its abuse liability. The aim of this study was to further characterize patterns of pregabalin users from substance abuse treatment facilities and detect changes in users profile over the study period. Methods The data source was the Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse (OPPIDUM) program, an annual, repeated, cross-sectional, nationwide, multicenter survey that collects consumption data from patients with substance use disorders. First, we described the characteristics of pregabalin users and their consumption patterns. We compared these data between 2008 and 2018 (P1) and 2019 and 2022 (P2). Second, we conducted a multiple correspondence analysis to identify profiles of users. Results From 2008 to 2022, 291 pregabalin users (0.37% of all users) from 116 substance abuse treatment facilities were identified. The number of pregabalin users was lower than 15 per year in P1 (n = 89) and between 40 and 60 per year in P2 (n = 202). The number of users who reported pregabalin as the first substance leading to dependence increased significantly in P2 compared with P1 (p < 0.005). When comparing P2 with P1, there was a significant increase in precarity (p < 0.001), users in prison (p = 0.002), withdrawal symptoms (p < 0.001), dependence (p < 0.001), use of higher dose of pregabalin (p = 0.029), and acquisition by deal/street market (p < 0.001). The multiple correspondence analysis allowed for the identification of distinct profiles of pregabalin users: (i) a cluster with mainly users from P1, who presented a simple use of pregabalin, and were older (> 45 years), were involved in opioid agonist treatment (OAT), and obtained pregabalin legally; and (ii) a cluster with mainly users from P2, who presented pregabalin dependence, and were younger (< 26 years), reported pregabalin as the first substance leading to dependence, used doses higher than the market authorization, were in severe precarity, and were in prison. Conclusions These data showed that the profile of pregabalin users has changed in the last years. Pregabalin use disorders also affect users without history of addiction.Keywords
This publication has 37 references indexed in Scilit:
- The pain of pregabalin prescribing in prisonsBritish Journal of General Practice, 2013
- OPPIDUM surveillance program: 20 years of information on drug abuse in FranceFundamental & Clinical Pharmacology, 2013
- Pregabalin abuse and dependence in Germany: results from a database queryEuropean Journal of Clinical Pharmacology, 2013
- Pregabalin Misuse–Related Issues; Intake of Large Dosages, Drug-Smoking Allegations, and Possible Association With MyositisJournal of Clinical Psychopharmacology, 2012
- MissForest—non-parametric missing value imputation for mixed-type dataBioinformatics, 2011
- The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trialsEpilepsia, 2011
- Is There a Recreational Misuse Potential for Pregabalin Analysis of Anecdotal Online Reports in Comparison with Related Gabapentin and Clonazepam DataPsychotherapy and Psychosomatics, 2011
- A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting systemEuropean Journal of Clinical Pharmacology, 2010
- Évaluation des conduites addictives chez les personnes entrant en milieu pénitentiaire à partir du programme OPPIDUM du réseau des centres d’évaluation et d’information sur la pharmacodépendance (CEIP)L'Encéphale, 2010
- Observation of Psychoactive Substance Consumption: Methods and Results of the French OPPIDUM ProgrammeEuropean Addiction Research, 2001